Research reveals GLP-1 and SGLT-2 medications may lower COPD exacerbation risk in diabetes, offering new hope for dual condition management.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

Looking to treat yourself to a relaxing spa treatment? Salt is the key ingredient at the Himalayan Salt Cave Spa and Float in ...

University at Buffalo School of Nursing researchers have identified a new benefit of mindfulness for people managing chronic ...

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease (COPD) after showing a clear benefit in a phase 3 trial. The headline ...

“This could influence treatment decisions and improve respiratory ... to figure out how we can minimize the incidence of COPD as a new patient developing COPD,” he added.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024More prescriptions filled through February ...